Q4 2025 Zevra Therapeutics Inc Earnings Call Transcript
Key Points
- Zevra Therapeutics Inc (ZVRA) reported strong financial performance with net revenue of $106.5 million for 2025, driven by MIPLYFFA sales of $87.4 million.
- The company successfully enrolled 52 patients in the first full year of MIPLYFFA commercialization, indicating strong market penetration.
- Zevra is expanding access to MIPLYFFA globally through its expanded access program, with 113 patients enrolled by the end of 2025.
- The company has submitted a marketing authorization application to the European Medicines Agency for MIPLYFFA, supported by a robust data package.
- Zevra is actively pursuing a patent term extension for MIPLYFFA, which could provide additional exclusivity and upside potential.
- Operating expenses increased to $23 million in Q4 2025, with SG&A expenses rising by $4.3 million compared to the same quarter in 2024.
- The company faces variability in ordering patterns and enrollment rates for its global expanded access program, which could impact revenue consistency.
- Zevra's ongoing Phase 3 DISCOVER study for Celiprolol has only enrolled 52 of the planned 150 patients, indicating slower than anticipated progress.
- The company anticipates variability in MIPLYFFA sales due to the ultra-rare nature of the disease and the small patient population.
- Zevra's gross to net revenue ratio is subject to change due to dynamic factors, including the Inflation Reduction Act, affecting financial predictability.
Good afternoon, and thank you for joining Zevra's fourth quarter and full year 2025 financial results and corporate update conference call. Today's call is being recorded and will be available via the Investor Relations section of the company's website later today.
The host for today's call is Nichol Ochsner, Zevra's Vice President of Investor Relations and Corporate Communications.
Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our fourth quarter and full year 2025 financial results. I encourage you to read the financial results news release, which was distributed this afternoon, and is available in the Investors section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
